Natera Says Study Suggests Signatera May Help Older Breast Cancer Patients Avoid Surgery

MT Newswires Live03-31 18:57

Natera (NTRA) said Tuesday that a study published in Clinical Cancer Research found its Signatera test helped identify older women with early-stage ER+/HER2- breast cancer who could be treated with primary endocrine therapy without surgery.

The prospective study followed 43 women aged 70 years and older with stage 1-3 breast cancer who chose endocrine therapy instead of surgery, Natera said.

Baseline testing showed 68% of patients were molecular residual disease-negative, and none experienced disease progression, Natera said.

Among patients who tested MRD-positive at baseline, 64% cleared circulating tumor DNA after six months of treatment and remained free of distant progression, the company said.

Tumor progression occurred in five patients, all of whom tested MRD-positive before imaging detected changes, suggesting 100% longitudinal sensitivity in the study, Natera said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment